Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News on Pharma

Analyst Favors Cigna, Alignment Healthcare, Cautious On Peers

Cigna Group’s (NYSE:CI) Evernorth Health Services announced on Tuesday a $3.5 billion investment in Shields Health Solutions, a specialty pharmacy management company.

Benzinga

Upstream's New Sinus Treatment Cuts Need For Surgery, Early Trial Finds

The medical landscape for chronic rhinosinusitis is rapidly advancing, with new treatments offering hope for improved quality of life for patients. As pharmaceutical companies race to develop effective therapies, recent clinical trials are shedding light on promising solutions.

Benzinga

Why Carisma Therapeutics Shares Are Trading Higher By 133%; Here Are 20 Stocks Moving Premarket

Shares of Carisma Therapeutics, Inc. (NASDAQ:CARM) rose sharply in pre-market trading after the company announced it will receive a $5 million investment from Ocugen as part of a merger with Ocugen’s subsidiary OrthoCelix.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Police Raid Suizo Argentina and Disability Agency in Explosive Graft Probe Tied to Milei's Sister

Argentine President Javier Milei's sister, Karina Milei, is accused of taking a 3% cut in a Suizo Argentina pharmaceutical deal with the National Disability Agency. Police raids, leaked recordings, and election-year tensions intensify the scandal.

Latin Times

Singapore is worried about a rise in drug-laced vaping. What is happening, and what is the drug etomidate?

Vaping has been banned since 2018, but now authorities are seeing a rise in young people using them to take an anaesthetic agent

The Guardian - AU

Who is Jim O’Neill? CDC chief set to bolster RFK Jr plan to remake vaccine policy

Ally of health secretary worked as speechwriter in George W Bush administration and has no training in medicine

The Guardian - US

Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda

As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major players to seek FDA approvals for generic versions of popular medications, reshaping the competitive landscape and providing more choices for consumers.

Benzinga

Read news from The Economist, FT, and more,
with one subscription

Telix Gets Second FDA Rejection For Kidney Cancer Drug

On Thursday, Telix Pharmaceuticals Limited (NASDAQ:TLX) received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for the Biologics License Application (BLA) for TLX250-CDx (Zircaix, 89Zr-DFO girentuximab), an investigational PET2 agent for the diagnosis and characterization of renal masses as clear cell renal cell carcinoma (ccRCC).

Benzinga

What's Going On With Tilray Stock Today?

Tilray Brands, Inc. (NASDAQ:TLRY) shares gained ground on Thursday after the marijuana company’s medical division expanded its portfolio in Germany with three newly certified cannabis strains.

Benzinga

FDA Rejects Outlook Therapeutics Eye Drug For Second Time

Outlook Therapeutics, Inc. (NASDAQ:OTLK) stock plunged on Thursday after the U.S. Food and Drug Administration (FDA) update.

Benzinga

Top 5 Biotech Stocks With Strong Momentum

Among biotechnology stocks, several names have hovered around the top momentum percentile this week, signaling robust bullish activity and potential for short-term gains.

Benzinga

Mounjaro maker pauses shipments of weight loss drug to UK

US firm Eli Lilly reportedly tells British wholesalers to stop taking orders as demand soars before September price rise

The Guardian - UK

Mounjaro weight loss jab sales are halted in the UK as drugmaker looks to beat price rise

Eli Lilly, the manufacturer of Mounjaro, has temporarily suspended deliveries of the drug to UK pharmacies in response to ‘unprecedented demand’

Evening Standard

Why MongoDB Shares Are Trading Higher By 31%; Here Are 20 Stocks Moving Premarket

Shares of MongoDB, Inc. (NASDAQ:MDB) rose sharply in pre-market trading after the company posted better-than-expected second-quarter results after the closing bell on Tuesday.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Texas Tribune

Texas Legislature approves bill making ivermectin an over-the-counter drug

Some people use the drug to treat COVID, even though it’s not approved by the FDA for such use. The bill now awaits the governor’s signature.

The Guardian - UK

Tough talk from Streeting – but he still needs a deal with big pharma

Health secretary calls industry ‘shortsighted’ but there is danger in giving UK better terms than much of rich Europe

Benzinga

NovaBay Pharmaceuticals Stock Soars 48% After Hours, Following Special Dividend Declaration

NovaBay Pharmaceuticals Inc. (NYSEAMERICAN: NBY) shares jumped 48.31% in after-hours trading on Tuesday, reaching $1.32 after closing the regular session at $0.89. The biotech company’s board declared a one-time special cash dividend of $0.80 per share.

Evening Standard

Pharmacists ‘using personal finances and remortgaging to keep businesses afloat’

It comes as a survey found almost four in 10 pharmacies are unable to pay bills for medication on time.

Get all your
news in one place.

100’s of premium titles.
One news app.

Benzinga

Nvidia Q2 Preview: 'Saying This Is The Most Important Stock In The World Is An Understatement' (CORRECTED)

CORRECTION: Nvidia’s stock price in the price action section was incorrect. It has been corrected/updated.

Benzinga

Gyre Therapeutics Gains Attention As Under-The-Radar Liver Fibrosis Drug Maker

The global biopharmaceutical landscape is rapidly evolving, driven by innovations targeting complex diseases like organ fibrosis and liver conditions. As companies push the boundaries of medical science, new therapies are emerging that promise to transform patient care and redefine market leadership in these critical areas.

Benzinga

CareDx Battles Reimbursement Uncertainty As Market Overlooks Long-Term Potential

CareDx, Inc. (NASDAQ:CDNA) faces fresh uncertainty as proposed reimbursement changes threaten its core testing business, clouding near-term growth even as the company’s expanding transplant solutions platform positions it for long-term opportunity in an $8 billion market.

Benzinga

Why Serina Therapeutics Shares Are Trading Higher By Over 25%; Here Are 20 Stocks Moving Premarket

Shares of Serina Therapeutics Inc (NYSE:SER) rose sharply in pre-market trading after the company announced the FDA has provided written feedback supporting the advancement of SER-252.

Benzinga

Options Corner: Why The Market Could Be Prescribing A Bull Call Spread For Gilead Sciences

While all publicly traded enterprises aim for business success, achieving it can also ironically lead to valuation pressures. That's the tough lesson that pharmaceutical giant Gilead Sciences, Inc. (NASDAQ:GILD) learned the hard way recently. Although the company delivered the goods for its latest financial disclosure, post-earnings digestion appears to have…

Benzinga

FDA Flags Alarming Contamination At Novo Nordisk Indiana Plant, Including Cat Hair, Bacteria, And Foreign Particles

The U.S. Food and Drug Administration (FDA) has identified repeated quality control failures, including foreign particle contamination, inadequate investigations, and insufficient corrective actions at the Novo Nordisk A/S (NYSE:NVO) operated facility in Bloomington, Indiana.

Benzinga

BeOne Cashes In On Amgen's Cancer Drug Royalties In Multibillion-Dollar Pharma Tie-Up

BeOne Medicines Ltd. (NASDAQ:ONC) on Monday agreed to sell its royalty rights on the worldwide sales, excluding China, of Amgen Inc.’s (NASDAQ:AMGN) Imdelltra (tarlatamab-dlle) for up to $950 million to Royalty Pharma Inc. (NASDAQ:RPRX).

1 … 11 12 13 14

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.